Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2046267 Target Snapshot

Anoctamin-1 · SINGLE PROTEIN · Homo sapiens

429Compounds
32Assays
2Approved Drugs
669.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Anoctamin-1 shows approved-linked disease relevance led by Diarrhea. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q5XXA6. Start with Diarrhea, then reuse UniProt Q5XXA6 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Diarrhea, then reuse UniProt Q5XXA6 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Diarrhea

Anoctamin-1 shows approved-linked disease relevance led by Diarrhea. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Diarrhea because it currently carries approved-linked support. Linked drugs include CROFELEMER. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Anoctamin-1 as ChEMBL target CHEMBL2046267, mapped to UniProt Q5XXA6. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Anoctamin-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2046267
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q5XXA6
Anoctamin-1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Anoctamin-1 is the right protein anchor across sources, using UniProt Q5XXA6 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Diarrhea is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAnoctamin-1
UniProt AccessionQ5XXA6
Component TypeProtein
Sequence Length986 aa

Anoctamin-1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Anoctamin-1, mapped to UniProt Q5XXA6. Sequence length is 986 aa.

Mapped IDQ5XXA6
Review nameAnoctamin-1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Anoctamin-1 shows approved-linked disease relevance led by Diarrhea. 2 more disease programs remain visible in the same review block.

Approved-linked Approved
Diarrhea
1 linked drug · 1 direct · 1 efficacy
Linked drugCROFELEMER
Clinical signal Phase II
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugCROFELEMER
Clinical signal Phase II
irritable bowel syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugCROFELEMER
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with Diarrhea because it currently carries approved-linked support. Linked drugs include CROFELEMER. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseDiarrhea
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
Assay Mix

Activity Type Distribution

IC50203.0
EC50466.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5748528 8.0 EC50 10.0 Preclinical
CHEMBL5818335 8.0 EC50 10.0 Preclinical
CHEMBL5944799 8.0 EC50 10.0 Preclinical
CHEMBL5987751 8.0 EC50 10.0 Preclinical
CHEMBL5888912 7.7 EC50 20.0 Preclinical
CHEMBL5923346 7.7 EC50 20.0 Preclinical
CHEMBL6027216 7.7 EC50 20.0 Preclinical
CHEMBL6035973 7.7 EC50 20.0 Preclinical
CHEMBL6063625 7.7 EC50 20.0 Preclinical
CHEMBL4445544 7.68 IC50 21.0 Preclinical
Distribution

pChEMBL Value Distribution

40
5.0
92
5.5
198
6.0
167
6.5
54
7.0
19
7.5
6
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

NITAZOXANIDE
CHEMBL1401
Approved 2002
NICLOSAMIDE
CHEMBL1448
Approved 1982
Assay Landscape

Assay Landscape

32
Total Assays
593
Tested Compounds
1
Assay Types
Binding — 32 assays, 593 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 27 348 6.2
single protein format 4 230 6.5
assay format 1 15 5.3

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine